AstraZeneca's diabetes drug curbs heart failure, kidney risks

Diabetics are at increased risk of heart problems, making the CV profile of drugs to treat the condition an important focus for doctors and patients.Dr Stephen Wiviott of Brigham and Women's Hospital in Boston, a senior investigator on the trial, said the findings were important in building up a clearer picture of SGLT2 drugs, which until now have been targeted at patients with established heart disease.AstraZeneca hopes the new data will help expand the use of Farxiga to a much wider range of p